News + Resources
Innovations Advanced by M&A: Opdivo and Yervoy’s Substantial Impact on Cancer Treatment
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series here:...
“Fast Facts”: Early-Stage Companies Count on M&A to Bring Biopharmaceutical Breakthroughs to Patients
The United States is home to more than 2,300 life sciences companies – including more than 85 percent of the world’s small, early-stage biopharmaceutical companies – each competing to bring new treatments and cures to patients. Within this dynamic and competitive...
Innovations Advanced by M&A: The First Therapy for Pompe Disease
This blog is another installment in our series, Innovations Advanced by M&A, which underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series...
House Committee on Small Business Urges FTC, DOJ to Consider Consequences of Recent Merger Guidelines on Early-Stage Companies
Bipartisan policymakers continue to raise concerns about the recently finalized 2023 Merger Guidelines and their impact on early-stage companies. Last week, the House Committee on Small Business wrote to the Federal Trade Commission (FTC) and Antitrust Division of the...
‘Material Differences’ & ‘Less Burden’: FTC, DOJ Signal Forthcoming Changes to Proposed HSR Rules
Speaking to antitrust experts at the ABA’s 2024 Spring Antitrust Meeting, Andrew Forman, deputy assistant attorney general at the Department of Justice’s (DOJ) Antitrust division, suggested that the Federal Trade Commission (FTC) and DOJ’s forthcoming changes to the...